RT Journal Article
SR Electronic
T1 Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6861
OP 6867
VO 35
IS 12
A1 MASANORI KOMATSU
A1 YASUHIRO ARAI
A1 KENICHIRO YABUKI
A1 DAISUKE SANO
A1 OSAMU SHIONO
A1 YASUNORI SAKUMA
A1 GOUSHI NISHIMURA
A1 MASAHIRO TAKAHASHI
A1 TAKAHIDE TAGUCHI
A1 NOBUHIKO ORIDATE
YR 2015
UL http://ar.iiarjournals.org/content/35/12/6861.abstract
AB Background/Aim: Several randomized trials have shown that concurrent chemoradiotherapy (CCRT) either with or without adjuvant chemotherapy is more effective than radiotherapy-alone for treating nasopharyngeal carcinoma (NPC). The present study retrospectively evaluated the efficacy and toxicity of CCRT with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy in patients with NPC. Patients and Methods: The study regimen consisted of two cycles of TPF chemotherapy [docetaxel (90 mg/m2), cisplatin (60 mg/m2), and continuous 5-fluorouracil (600 mg/m2/day: 5 days)] during definitive radiotherapy. Radiotherapy was performed 5 days a week with a single daily fraction of 1.8 or 2.0 Gy totalling to 70-Gy doses. A total of 24 patients with NPC were enrolled and evaluated. Results: Treatment completion rate was 70.8%, with an overall response rate of 100%. The 5-year overall survival rate was 82.4%, and 5-year progression-free survival rate was 78.3%. Conclusion: CCRT with TPF resulted in excellent survival rates for patients with NPC.